Pariet^®

Rabeprazole sodium
Click here for the Pariet Medicines Guide

Background

Pariet^® (rabeprazole sodium) belongs to a class of medicines called Proton Pump Inhibitors (PPIs).

Rabeprazole is used to treat gastric acid-related disorders in adults.

Gastro-intestinal disorders

Rabeprazole tablets are used to treat people diagnosed as having active duodenal ulcer, active benign gastric/stomach ulcer (peptic ulcers), symptomatic erosive or ulcerative gastro-oesophageal reflux disease (GORD) commonly referred to as inflammation of the gullet caused by acid and associated with heartburn, or for long-term treatment of GORD (GORD maintenance).

Rabeprazole tablets are also used for the symptomatic treatment of moderate to very severe gastro-oesophageal reflux disease (symptomatic GORD) also associated with heartburn.

Clinical Action

Rabeprazole tablets act by reducing the amount of acid made by the stomach. This allows ulcers to heal and symptoms of pain to improve. Rabeprazole is also sometimes given to patients whose stomachs make extremely high amounts of acid, a condition called Zollinger-Ellison Syndrome. In combination with two antibiotics (clarithromycin and amoxycillin) rabeprazole tablets are used for the eradication of H pylori infection in patients with peptic ulcer disease.

Further Information

Rabeprazole was first launched in 1997 (1998 in Europe) in co-promotion with Janssen-Cilag and is now available in 72 countries.

The Summary of Product Characteristics and the Patient Information Leaflet (PIL), can be found at www.emc.medicines.org.uk.

If you are not a healthcare professional and have any questions or concerns, please consult your healthcare professional directly

Adverse Events

All medicines may have side-effects. Please consult the patient information leaflet for a full list of side effects associated with the use of Pariet - see link above.